Vir Biotechnology Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Cash & Equivalents	278.73	232.19	222.95	241.58	848.63	347.82
Short-Term Investments	254	234.83	682.4	1,281	1,553	360.33
Cash & Short-Term Investments	532.73	467.02	905.35	1,522	2,402	708.15
Cash Growth	-12.09%	-48.42%	-40.53%	-36.62%	239.20%	-3.90%
Other Receivables	-	-	-	-	-	773.08
Total Trade Receivables	-	-	-	-	-	773.08
Other Current Assets	41.01	47.07	137.11	65.82	117.04	81.6
Total Current Assets	573.74	514.08	1,042	1,588	2,519	1,563
Net Property, Plant & Equipment	109.82	117.72	122.86	167.2	188.17	130.05
Other Intangible Assets	7.7	7.85	8.12	22.57	32.76	33.29
Goodwill	16.94	16.94	16.94	16.94	16.94	16.94
Long-Term Investments	475.02	314.58	190.02	105.28	23.93	201.39
Other Long-Term Assets	31.59	31.66	18.42	18.86	21.23	9.78
Total Assets	1,215	1,003	1,399	1,919	2,802	1,954
Accounts Payable	17.75	9.8	5.08	6.33	6.42	6.52
Accrued Expenses	77.21	83.01	98.52	104.22	489.09	236.51
Unearned Revenue	-	-	-	64.85	15.52	98.21
Other Current Liabilities	-	-	16.06	-	-	-
Total Current Liabilities	94.96	92.82	119.66	175.41	511.03	341.24
Long-Term Leases	84.14	89.05	90.14	111.67	123.84	133.56
Other Long-Term Liabilities	53.22	55.68	38.63	41.74	89.26	47.62
Total Long-Term Liabilities	137.35	144.73	128.77	153.42	213.1	181.18
Total Liabilities	232.31	237.55	248.43	328.82	724.13	522.42
Common Stock	0.02	0.01	0.01	0.01	0.01	0.01
Additional Paid-in Capital	2,230	1,965	1,912	1,829	1,710	1,572
Accumulated Other Comprehensive Income	-4.6	-2.06	-1.72	-0.82	-9.12	-1.1
Retained Earnings	-	-	-	-237.82	377.24	-138.6
Shareholders' Equity	2,226	1,963	1,910	1,590	2,078	1,432
Total Liabilities & Equity	1,215	1,003	1,399	1,919	2,802	1,954
Total Debt	84.14	89.05	90.14	111.67	123.84	133.56
Net Cash (Debt)	448.59	377.96	815.21	1,411	2,278	574.58
Net Cash Growth	-12.49%	-53.64%	-42.21%	-38.08%	296.50%	-14.28%
Net Cash Per Share	3.02	2.73	5.98	10.52	16.90	4.31
Book Value	2,226	1,963	1,910	1,590	2,078	1,432
Book Value Per Share	14.98	14.17	14.02	11.86	15.41	10.73
Tangible Book Value	2,201	1,938	1,885	1,551	2,028	1,382
Tangible Book Value Per Share	14.81	13.99	13.84	11.56	15.05	10.35

SEC Filings: 10-K · 10-Q